ARTICLE | Product Development
Pfizer looking to RSV vaccine for fresh growth
Data in maternal setting set pharma up to seek approval this year
November 2, 2022 1:03 AM UTC
A second Phase III RSV readout from Pfizer puts the pharma on track for a potential vaccine approval where competitors have fallen short.
Along with its 3Q22 earnings Tuesday, Pfizer Inc. (NYSE:PFE) said RSVpreF delivered efficacy of 81.8% against severe medically attended lower respiratory track illness (MA-LRTI) in infants from birth through the first 90 days of life in the Phase III MATISSE trial in which the respiratory syncytial virus (RSV) vaccine is given to pregnant women to protect newborns. ...
BCIQ Company Profiles